article thumbnail

Developing a first-in-class small molecule drug for inflammatory disease

European Pharmaceutical Review

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

article thumbnail

Patient Centricity for Pharma Marketing – Quiz

PharmaState Academy

a) Maximizing Profits through maximum patient's care b) Putting Patients First c) Regulatory Compliance and patient outcome d) Internal Processes improvement to improve patient's health outcomes 5 / 20 How can patient-centric marketing contribute to better healthcare outcomes?

Dosage 59